Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Non-Interventional Study Comparing Standard of Care Osimertinib +/- Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients

NCT06538038 is registered in ClinicalTrials.gov with PrECOG, LLC. as lead sponsor.

NCT NCT06538038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06538038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Non-Interventional Study Comparing Standard of Care Osimertinib +/- Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients
Lead sponsor
PrECOG, LLC.
Phase
Observational
Overall status
Active, not recruiting
Start date
September 17, 2024
Completion date
August 31, 2029
Enrollment
200 (actual)
Sites
146

Conditions

As the registry lists them; a condition with its own page is linked.

epidermal growth factor receptor gene mutation, non small cell lung cancer, stage iii lung cancer, stage iv lung cancer